Pharma has a timing problemand its getting more expensive.
In a world where launches are won (or lost) long before the first prescription is written, the patent first mindset is quickly becoming the difference between capturing market share and watchin…

Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In mergers, acquisitions, and strategic investments, the hard part of diligence is often assumed to be financialrevenue quality, pipeline math, manufacturing capacity,…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Teams Miss Until Its Too Late
In the pharma world, the race is never just about getting a drug approved. Its about staying approvedcommercially and legallyafter the initial launch. And thats where a…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple countdown: Patent term ends in ~20 years, then the market opens. In reality, the clock is messierand the outcome is often decided long b…

Pharma mega-deals dont start with a handshake. They start with a clock.
Behind every headline acquisition, licensing agreement, or strategic partnership is a quieter, more consequential question: How long can the seller keep exclusivityand how much of …

The Patent Cliff Isnt a CliffIts a Countdown. Heres How to Forecast Drug Price Erosion Before It Hits.
If you work in pharma, youve heard the phrase patent cliff so often it can start to sound like weatherinevitable, distant, and impossible to influenc…

Post-Approval Patent Strategy: The Quiet Phase Where Drug Value Is Won (or Lost)
Most teams obsess over the pre-approval patent planclaims, filings, prosecution strategy, and the race to secure exclusivity before the first launch. But the real inflecti…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies dont lose exclusivity because they miss a filing. They lose it because they misread the battlefield.
In patent strategy, the real risk isnt just litigationits unforced errors: weak claim construction positions, sloppy infringement narr…